Dermira acquired by Eli Lilly
Eli Lilly agreed to acquire Dermira, a dermatology solutions brand, on Jan 10, 2020.
Transaction summary
- Target
- Dermira
- Acquirer
- Eli Lilly
- Seller
- -
- Announced
- 2020-01-10
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
100% enterprise value
USD 1.1B
100% enterprise value | USD
Basis: FundComb estimate
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Transaction Value: USD 1.1B
Spreadsheet update from FCR-121 Dermira unit correction ? Lilly primary release
Basis
- Estimated transaction value: USD 1.1bn.
Source summary
Lilly Announces Agreement to Acquire Dermira | Eli Lilly and Company - investor.lilly.com
ConfirmedContinue your research
Related transaction comps
Dersimelagon rights acquired by LEO Pharma
2026-08-18 · Confirmed
View transaction → dermatologyLamisil acquired by Karo Healthcare
2023-08-01 · Confirmed
View transaction → biopharmaceuticalsOyster Point Pharma acquired by Viatris
2022-11-07 · Confirmed
View transaction → biopharmaceuticalsBiohaven Pharmaceutical acquired by Pfizer
2022-05-10 · Confirmed
View transaction →